Parallax Volatility Advisers
VKTX icon

Parallax Volatility Advisers’s Viking Therapeutics VKTX Stock Holding History

Parallax Volatility Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-600
Closed -$15.9K – 1832
2025
Q2 		$15.9K Sell
600
-72,300
-99% -$1.9M ﹤0.01% 1480
2025
Q1 		$1.76M Sell
72,900
-72,200
-50% -$2.28M ﹤0.01% 901
2024
Q4 		$5.84M Sell
145,100
-12,600
-8% -$718K 0.01% 770
2024
Q3 		$9.98M Buy
157,700
+106,500
+208% +$6.25M 0.02% 550
2024
Q2 		$2.71M Hold
51,200
– – 0.01% 930
2024
Q1 		$4.2M Sell
51,200
-2,200
-4% -$97.9K 0.01% 791
2023
Q4 		$994K Buy
53,400
+2,200
+4% +$28.8K ﹤0.01% 1411
2023
Q3 		$567K Buy
51,200
+900
+2% +$12.9K ﹤0.01% 1552
2023
Q2 		$815K Buy
50,300
+50,000
+16,667% +$1.05M ﹤0.01% 1485
2023
Q1 		$5K Buy
+300
New +$3.1K ﹤0.01% 2479
2019
Q2 		– Sell
-63,500
Closed -$632K – 3824
2019
Q1 		$632K Buy
+63,500
New +$532K ﹤0.01% 1438

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parallax Volatility Advisers's VKTX Position: Q3 2025 in Review

Parallax Volatility Advisers sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 35,540 shares — an estimated $942K sold.

Parallax Volatility Advisers first reported a position in VKTX in Q4 2017 and held it in 14 quarters. The position peaked at $10.8M in Q4 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Parallax Volatility Advisers reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 35,540 Viking Therapeutics shares in Q3 2025, an estimated $942K.
  • Parallax Volatility Advisers first reported a position in Viking Therapeutics in Q4 2017 and held it in 14 quarters.
  • Parallax Volatility Advisers's Viking Therapeutics position peaked at $10.8M in Q4 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Parallax Volatility Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.